HomeCompareCSAMF vs ABBV

CSAMF vs ABBV: Dividend Comparison 2026

CSAMF yields 9.90% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CSAMF wins by $407896.01M in total portfolio value
10 years
CSAMF
CSAMF
● Live price
9.90%
Share price
$4.82
Annual div
$0.48
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$407896.11M
Annual income
$400,131,239,290.63
Full CSAMF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — CSAMF vs ABBV

📍 CSAMF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCSAMFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CSAMF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CSAMF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CSAMF
Annual income on $10K today (after 15% tax)
$841.44/yr
After 10yr DRIP, annual income (after tax)
$340,111,553,397.04/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, CSAMF beats the other by $340,111,532,341.03/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CSAMF + ABBV for your $10,000?

CSAMF: 50%ABBV: 50%
100% ABBV50/50100% CSAMF
Portfolio after 10yr
$203948.11M
Annual income
$200,065,632,031.20/yr
Blended yield
98.10%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CSAMF
No analyst data
Altman Z
1.1
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CSAMF buys
0
ABBV buys
7
PoliticianChamberTickerTypeAmountDate
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-11-13
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$ABBV▲ Buy$1,001 - $15,0002025-10-30
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-08-14
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCSAMFABBV
Forward yield9.90%3.06%
Annual dividend / share$0.48$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$407896.11M$102.3K
Annual income after 10y$400,131,239,290.63$24,771.77
Total dividends collected$407370.38M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CSAMF vs ABBV ($10,000, DRIP)

YearCSAMF PortfolioCSAMF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$12,680$1,979.87$11,550$430.00+$1.1KCSAMF
2$18,260$4,692.42$13,472$627.96+$4.8KCSAMF
3$32,169$12,630.66$15,906$926.08+$16.3KCSAMF
4$76,012$41,591.87$19,071$1,382.55+$56.9KCSAMF
5$265,032$183,698.34$23,302$2,095.81+$241.7KCSAMF
6$1,480,778$1,197,194.33$29,150$3,237.93+$1.45MCSAMF
7$14,087,114$12,502,681.79$37,536$5,121.41+$14.05MCSAMF
8$237,394,699$222,321,486.64$50,079$8,338.38+$237.34MCSAMF
9$7,256,891,462$7,002,879,134.27$69,753$14,065.80+$7256.82MCSAMF
10$407,896,113,155$400,131,239,290.63$102,337$24,771.77+$407896.01MCSAMF

CSAMF vs ABBV: Complete Analysis 2026

CSAMFStock

CSAM Health Group AS provides various ehealth solutions in Norway and internationally. The company offers CSAM Arcidis, an integrated system for teleradiology; CSAM DICOM Server for handling radiology data; CSAM HelseMail for transfer of confidential patient data between healthcare organizations; CSAM Infobroker, a vendor-neutral telemedicine system for radiology that enables multiple clinicians to share resources and knowledge; CSAM S7, a platform for self-care and health counselling; CSAM Web Client, a web-based user interface and connectivity solution that allows users to access multiple CSAM applications and functions; and CSAM XDS, a central archive for storing and managing various types of clinical patient data. It also provides CSAM Cardio, an ECG and diagnostic storage tool; CSAM CIMA, a mobile application for capturing, using, and sending medical media; CSAM Media, a web-based medical imaging solution; CSAM Medimaker for image management and workflow solution; CSAM Picsara, an image management solution; and CSAM TRIS, a radiology information system. In addition, the company offers CSAM Partus, a maternity information system; CSAM Natus, a maternity care system; CSAM iPana Labor Information System, a web-based labour information system; CSAM iPana Maternity, a cloud-based service platform that enables expectant mothers, hospitals, and maternity clinics to electronically collect, store, and share medical information; and CSAM Fertsoft, a care and practice management software. Further, it provides CSAM Optima Predict solution for operational planning; CSAM Optima Live; CSAM AMIS, an emergency medical information system; CSAM IMTS, a tool for assessing and prioritizing patients; CSAM Paratus, an emergency response system; CSAM CoordCom; CSAM ResQMobile; CSAM Cytodose, an oncology management solution; and CSAM ProSang, an advanced laboratory information management system. The company was founded in 1999 and is headquartered in Oslo, Norway.

Full CSAMF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CSAMF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CSAMF vs SCHDCSAMF vs JEPICSAMF vs OCSAMF vs KOCSAMF vs MAINCSAMF vs JNJCSAMF vs MRKCSAMF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.